Trial Outcomes & Findings for Behavioral Nudges to Improve Palliative Care Utilization in Advanced Cancer (NCT NCT05365997)
NCT ID: NCT05365997
Last Updated: 2025-02-05
Results Overview
Binary outcome (yes/no) measured at the patient level among eligible patients based on the date of documented palliative care encounter
Recruitment status
COMPLETED
Study phase
NA
Target enrollment
266 participants
Primary outcome timeframe
Within 12 weeks of the Index Visit
Results posted on
2025-02-05
Participant Flow
Unit of analysis: Clinician Pod
Participant milestones
| Measure |
Control
Usual Care
|
Intervention
Nudge group
|
|---|---|---|
|
Overall Study
STARTED
|
136 2
|
130 2
|
|
Overall Study
COMPLETED
|
136 2
|
130 2
|
|
Overall Study
NOT COMPLETED
|
0 0
|
0 0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Behavioral Nudges to Improve Palliative Care Utilization in Advanced Cancer
Baseline characteristics by cohort
| Measure |
Control
n=136 Participants
Usual Care
|
Intervention
n=130 Participants
Nudge group
|
Total
n=266 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
66.9 years
STANDARD_DEVIATION 13 • n=99 Participants
|
66 years
STANDARD_DEVIATION 12.7 • n=107 Participants
|
66.5 years
STANDARD_DEVIATION 12.9 • n=206 Participants
|
|
Sex: Female, Male
Female
|
74 Participants
n=99 Participants
|
73 Participants
n=107 Participants
|
147 Participants
n=206 Participants
|
|
Sex: Female, Male
Male
|
62 Participants
n=99 Participants
|
57 Participants
n=107 Participants
|
119 Participants
n=206 Participants
|
|
Race/Ethnicity, Customized
Race · White
|
129 Participants
n=99 Participants
|
123 Participants
n=107 Participants
|
252 Participants
n=206 Participants
|
|
Race/Ethnicity, Customized
Race · Black or African American
|
3 Participants
n=99 Participants
|
4 Participants
n=107 Participants
|
7 Participants
n=206 Participants
|
|
Race/Ethnicity, Customized
Race · Asian
|
3 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
3 Participants
n=206 Participants
|
|
Race/Ethnicity, Customized
Race · Mixed
|
0 Participants
n=99 Participants
|
1 Participants
n=107 Participants
|
1 Participants
n=206 Participants
|
|
Race/Ethnicity, Customized
Race · Unknown/not reported
|
1 Participants
n=99 Participants
|
2 Participants
n=107 Participants
|
3 Participants
n=206 Participants
|
|
Race/Ethnicity, Customized
Ethnicity · Hispanic
|
3 Participants
n=99 Participants
|
3 Participants
n=107 Participants
|
6 Participants
n=206 Participants
|
|
Race/Ethnicity, Customized
Ethnicity · non-Hispanic
|
133 Participants
n=99 Participants
|
127 Participants
n=107 Participants
|
260 Participants
n=206 Participants
|
|
Diagnosis
CNS
|
0 Participants
n=99 Participants
|
1 Participants
n=107 Participants
|
1 Participants
n=206 Participants
|
|
Diagnosis
Brain
|
1 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
1 Participants
n=206 Participants
|
|
Diagnosis
Head and neck
|
3 Participants
n=99 Participants
|
12 Participants
n=107 Participants
|
15 Participants
n=206 Participants
|
|
Diagnosis
Thoracic
|
0 Participants
n=99 Participants
|
1 Participants
n=107 Participants
|
1 Participants
n=206 Participants
|
|
Diagnosis
Lung
|
33 Participants
n=99 Participants
|
12 Participants
n=107 Participants
|
45 Participants
n=206 Participants
|
|
Diagnosis
Liver
|
1 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
1 Participants
n=206 Participants
|
|
Diagnosis
Pancreatic
|
4 Participants
n=99 Participants
|
2 Participants
n=107 Participants
|
6 Participants
n=206 Participants
|
|
Diagnosis
GI
|
17 Participants
n=99 Participants
|
7 Participants
n=107 Participants
|
24 Participants
n=206 Participants
|
|
Diagnosis
Colon/rectal/anal
|
30 Participants
n=99 Participants
|
16 Participants
n=107 Participants
|
46 Participants
n=206 Participants
|
|
Diagnosis
GYN
|
1 Participants
n=99 Participants
|
25 Participants
n=107 Participants
|
26 Participants
n=206 Participants
|
|
Diagnosis
GU
|
4 Participants
n=99 Participants
|
12 Participants
n=107 Participants
|
16 Participants
n=206 Participants
|
|
Diagnosis
Breast
|
25 Participants
n=99 Participants
|
25 Participants
n=107 Participants
|
50 Participants
n=206 Participants
|
|
Diagnosis
Melanoma
|
5 Participants
n=99 Participants
|
2 Participants
n=107 Participants
|
7 Participants
n=206 Participants
|
|
Diagnosis
Other
|
12 Participants
n=99 Participants
|
15 Participants
n=107 Participants
|
27 Participants
n=206 Participants
|
|
Advanced Solid Malignancy
|
131 Participants
n=99 Participants
|
128 Participants
n=107 Participants
|
259 Participants
n=206 Participants
|
|
Brain Metastasis
|
11 Participants
n=99 Participants
|
14 Participants
n=107 Participants
|
25 Participants
n=206 Participants
|
|
ECOG > 2
|
1 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
1 Participants
n=206 Participants
|
|
Uncontrolled symptoms
|
28 Participants
n=99 Participants
|
26 Participants
n=107 Participants
|
54 Participants
n=206 Participants
|
PRIMARY outcome
Timeframe: Within 12 weeks of the Index VisitBinary outcome (yes/no) measured at the patient level among eligible patients based on the date of documented palliative care encounter
Outcome measures
| Measure |
Control
n=136 Participants
Usual Care
|
Intervention
n=130 Participants
Nudge group
|
|---|---|---|
|
Completion of Palliative Care Visit
|
11 Participants
|
19 Participants
|
Adverse Events
Control
Serious events: 0 serious events
Other events: 0 other events
Deaths: 23 deaths
Intervention
Serious events: 0 serious events
Other events: 0 other events
Deaths: 15 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place